Pfizer, Medicus ink licensing deal worth up to $1B for antibody drug conjugate
Pfizer, Medicus ink licensing deal worth up to $1B for antibody drug conjugate Seeking Alpha
Covered in this story
Summary aggregated from Seeking Alpha's public RSS feed. The full reporting belongs to Seeking Alpha — please read it on their site.